RELEASE (REdressing Long-tErm Antidepressant uSE): protocol for a 3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1 in general practice

Background Many people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or ongoing need for medication, contributing to long-term use (> 12 months). Long-term antidepressant use is increasing internationally yet is...

Full description

Saved in:
Bibliographic Details
Published inCurrent controlled trials in cardiovascular medicine Vol. 24; no. 1; p. 615
Main Authors Wallis, Katharine A, Donald, Maria, Horowitz, Mark, Moncrieff, Joanna, Ware, Robert S, Byrnes, Joshua, Thrift, Karen, Cleetus, MaryAnne, Panahi, Idin, Zwar, Nicholas, Morgan, Mark, Freeman, Chris, Scott, Ian
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 28.09.2023
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background Many people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or ongoing need for medication, contributing to long-term use (> 12 months). Long-term antidepressant use is increasing internationally yet is not recommended for most people. Long-term use is associated with adverse effects including weight gain, sexual dysfunction, lethargy, emotional numbing and increased risk of falls and fractures. This study aims to determine the effectiveness of two multi-strategy interventions (RELEASE and RELEASE+) in supporting the safe cessation of long-term antidepressants, estimate cost-effectiveness, and evaluate implementation strategies. Methods Design 3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1. Setting: primary care general practices in southeast Queensland, Australia. Population: adults 18 years or older taking antidepressants for longer than 1 year. Practices will be randomised on a 1.5:1:1 ratio of Usual care:RELEASE:RELEASE+. Intervention: RELEASE for patients includes evidence-based information and resources and an invitation to medication review; RELEASE for GPs includes education, training and printable resources via practice management software. RELEASE+ includes additional internet support for patients and prescribing support including audit and feedback for GPs. Outcome measures: the primary outcome is antidepressant use at 12 months self-reported by patients. Cessation is defined as 0 mg antidepressant maintained for at least 2 weeks. Secondary outcomes: at 6 and 12 months are health-related quality of life, antidepressant side effects, well-being, withdrawal symptoms, emotional numbing, beliefs about antidepressants, depressive symptoms, and anxiety symptoms; and at 12 months 75% reduction in antidepressant dose; aggregated practice level antidepressant prescribing, and health service utilisation for costs. Sample size: 653 patients from 28 practices. A concurrent evaluation of implementation will be through mixed methods including interviews with up to 40 patients and primary care general practitioners, brief e-surveys, and study administrative data to assess implementation outcomes (adoption and fidelity). Discussion The RELEASE study will develop new knowledge applicable internationally on the effectiveness, cost-effectiveness, and implementation of two multi-strategy interventions in supporting the safe cessation of long-term antidepressants to improve primary health care and outcomes for patients. Trial registration ANZCTR, ACTRN12622001379707p. Registered on 27 October 2022. Keywords: Antidepressants, Discontinuation, Deprescribing, Primary care, Withdrawal, Tapering, Long-term antidepressant use, Randomised controlled trial
AbstractList Background Many people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or ongoing need for medication, contributing to long-term use (> 12 months). Long-term antidepressant use is increasing internationally yet is not recommended for most people. Long-term use is associated with adverse effects including weight gain, sexual dysfunction, lethargy, emotional numbing and increased risk of falls and fractures. This study aims to determine the effectiveness of two multi-strategy interventions (RELEASE and RELEASE+) in supporting the safe cessation of long-term antidepressants, estimate cost-effectiveness, and evaluate implementation strategies. Methods Design 3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1. Setting: primary care general practices in southeast Queensland, Australia. Population: adults 18 years or older taking antidepressants for longer than 1 year. Practices will be randomised on a 1.5:1:1 ratio of Usual care:RELEASE:RELEASE+. Intervention: RELEASE for patients includes evidence-based information and resources and an invitation to medication review; RELEASE for GPs includes education, training and printable resources via practice management software. RELEASE+ includes additional internet support for patients and prescribing support including audit and feedback for GPs. Outcome measures: the primary outcome is antidepressant use at 12 months self-reported by patients. Cessation is defined as 0 mg antidepressant maintained for at least 2 weeks. Secondary outcomes: at 6 and 12 months are health-related quality of life, antidepressant side effects, well-being, withdrawal symptoms, emotional numbing, beliefs about antidepressants, depressive symptoms, and anxiety symptoms; and at 12 months 75% reduction in antidepressant dose; aggregated practice level antidepressant prescribing, and health service utilisation for costs. Sample size: 653 patients from 28 practices. A concurrent evaluation of implementation will be through mixed methods including interviews with up to 40 patients and primary care general practitioners, brief e-surveys, and study administrative data to assess implementation outcomes (adoption and fidelity). Discussion The RELEASE study will develop new knowledge applicable internationally on the effectiveness, cost-effectiveness, and implementation of two multi-strategy interventions in supporting the safe cessation of long-term antidepressants to improve primary health care and outcomes for patients. Trial registration ANZCTR, ACTRN12622001379707p. Registered on 27 October 2022. Keywords: Antidepressants, Discontinuation, Deprescribing, Primary care, Withdrawal, Tapering, Long-term antidepressant use, Randomised controlled trial
Abstract Background Many people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or ongoing need for medication, contributing to long-term use (> 12 months). Long-term antidepressant use is increasing internationally yet is not recommended for most people. Long-term use is associated with adverse effects including weight gain, sexual dysfunction, lethargy, emotional numbing and increased risk of falls and fractures. This study aims to determine the effectiveness of two multi-strategy interventions (RELEASE and RELEASE+) in supporting the safe cessation of long-term antidepressants, estimate cost-effectiveness, and evaluate implementation strategies. Methods Design 3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1. Setting: primary care general practices in southeast Queensland, Australia. Population: adults 18 years or older taking antidepressants for longer than 1 year. Practices will be randomised on a 1.5:1:1 ratio of Usual care:RELEASE:RELEASE+. Intervention: RELEASE for patients includes evidence-based information and resources and an invitation to medication review; RELEASE for GPs includes education, training and printable resources via practice management software. RELEASE+ includes additional internet support for patients and prescribing support including audit and feedback for GPs. Outcome measures: the primary outcome is antidepressant use at 12 months self-reported by patients. Cessation is defined as 0 mg antidepressant maintained for at least 2 weeks. Secondary outcomes: at 6 and 12 months are health-related quality of life, antidepressant side effects, well-being, withdrawal symptoms, emotional numbing, beliefs about antidepressants, depressive symptoms, and anxiety symptoms; and at 12 months 75% reduction in antidepressant dose; aggregated practice level antidepressant prescribing, and health service utilisation for costs. Sample size: 653 patients from 28 practices. A concurrent evaluation of implementation will be through mixed methods including interviews with up to 40 patients and primary care general practitioners, brief e-surveys, and study administrative data to assess implementation outcomes (adoption and fidelity). Discussion The RELEASE study will develop new knowledge applicable internationally on the effectiveness, cost-effectiveness, and implementation of two multi-strategy interventions in supporting the safe cessation of long-term antidepressants to improve primary health care and outcomes for patients. Trial registration ANZCTR, ACTRN12622001379707p. Registered on 27 October 2022.
Many people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or ongoing need for medication, contributing to long-term use (> 12 months). Long-term antidepressant use is increasing internationally yet is not recommended for most people. Long-term use is associated with adverse effects including weight gain, sexual dysfunction, lethargy, emotional numbing and increased risk of falls and fractures. This study aims to determine the effectiveness of two multi-strategy interventions (RELEASE and RELEASE+) in supporting the safe cessation of long-term antidepressants, estimate cost-effectiveness, and evaluate implementation strategies. 3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1. Setting: primary care general practices in southeast Queensland, Australia. Population: adults 18 years or older taking antidepressants for longer than 1 year. Practices will be randomised on a 1.5:1:1 ratio of Usual care:RELEASE:RELEASE+. Intervention: RELEASE for patients includes evidence-based information and resources and an invitation to medication review; RELEASE for GPs includes education, training and printable resources via practice management software. RELEASE+ includes additional internet support for patients and prescribing support including audit and feedback for GPs. Outcome measures: the primary outcome is antidepressant use at 12 months self-reported by patients. Cessation is defined as 0 mg antidepressant maintained for at least 2 weeks. Secondary outcomes: at 6 and 12 months are health-related quality of life, antidepressant side effects, well-being, withdrawal symptoms, emotional numbing, beliefs about antidepressants, depressive symptoms, and anxiety symptoms; and at 12 months 75% reduction in antidepressant dose; aggregated practice level antidepressant prescribing, and health service utilisation for costs. Sample size: 653 patients from 28 practices. A concurrent evaluation of implementation will be through mixed methods including interviews with up to 40 patients and primary care general practitioners, brief e-surveys, and study administrative data to assess implementation outcomes (adoption and fidelity). The RELEASE study will develop new knowledge applicable internationally on the effectiveness, cost-effectiveness, and implementation of two multi-strategy interventions in supporting the safe cessation of long-term antidepressants to improve primary health care and outcomes for patients.
BackgroundMany people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or ongoing need for medication, contributing to long-term use (> 12 months). Long-term antidepressant use is increasing internationally yet is not recommended for most people. Long-term use is associated with adverse effects including weight gain, sexual dysfunction, lethargy, emotional numbing and increased risk of falls and fractures. This study aims to determine the effectiveness of two multi-strategy interventions (RELEASE and RELEASE+) in supporting the safe cessation of long-term antidepressants, estimate cost-effectiveness, and evaluate implementation strategies.MethodsDesign3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1. Setting: primary care general practices in southeast Queensland, Australia. Population: adults 18 years or older taking antidepressants for longer than 1 year. Practices will be randomised on a 1.5:1:1 ratio of Usual care:RELEASE:RELEASE+. Intervention: RELEASE for patients includes evidence-based information and resources and an invitation to medication review; RELEASE for GPs includes education, training and printable resources via practice management software. RELEASE+ includes additional internet support for patients and prescribing support including audit and feedback for GPs. Outcome measures: the primary outcome is antidepressant use at 12 months self-reported by patients. Cessation is defined as 0 mg antidepressant maintained for at least 2 weeks. Secondary outcomes: at 6 and 12 months are health-related quality of life, antidepressant side effects, well-being, withdrawal symptoms, emotional numbing, beliefs about antidepressants, depressive symptoms, and anxiety symptoms; and at 12 months 75% reduction in antidepressant dose; aggregated practice level antidepressant prescribing, and health service utilisation for costs. Sample size: 653 patients from 28 practices. A concurrent evaluation of implementation will be through mixed methods including interviews with up to 40 patients and primary care general practitioners, brief e-surveys, and study administrative data to assess implementation outcomes (adoption and fidelity).DiscussionThe RELEASE study will develop new knowledge applicable internationally on the effectiveness, cost-effectiveness, and implementation of two multi-strategy interventions in supporting the safe cessation of long-term antidepressants to improve primary health care and outcomes for patients.Trial registrationANZCTR, ACTRN12622001379707p. Registered on 27 October 2022.
BACKGROUNDMany people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or ongoing need for medication, contributing to long-term use (> 12 months). Long-term antidepressant use is increasing internationally yet is not recommended for most people. Long-term use is associated with adverse effects including weight gain, sexual dysfunction, lethargy, emotional numbing and increased risk of falls and fractures. This study aims to determine the effectiveness of two multi-strategy interventions (RELEASE and RELEASE+) in supporting the safe cessation of long-term antidepressants, estimate cost-effectiveness, and evaluate implementation strategies.METHODSDESIGN: 3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1.SETTINGprimary care general practices in southeast Queensland, Australia.POPULATIONadults 18 years or older taking antidepressants for longer than 1 year. Practices will be randomised on a 1.5:1:1 ratio of Usual care:RELEASE:RELEASE+.INTERVENTIONRELEASE for patients includes evidence-based information and resources and an invitation to medication review; RELEASE for GPs includes education, training and printable resources via practice management software. RELEASE+ includes additional internet support for patients and prescribing support including audit and feedback for GPs.OUTCOME MEASURESthe primary outcome is antidepressant use at 12 months self-reported by patients. Cessation is defined as 0 mg antidepressant maintained for at least 2 weeks.SECONDARY OUTCOMESat 6 and 12 months are health-related quality of life, antidepressant side effects, well-being, withdrawal symptoms, emotional numbing, beliefs about antidepressants, depressive symptoms, and anxiety symptoms; and at 12 months 75% reduction in antidepressant dose; aggregated practice level antidepressant prescribing, and health service utilisation for costs.SAMPLE SIZE653 patients from 28 practices. A concurrent evaluation of implementation will be through mixed methods including interviews with up to 40 patients and primary care general practitioners, brief e-surveys, and study administrative data to assess implementation outcomes (adoption and fidelity).DISCUSSIONThe RELEASE study will develop new knowledge applicable internationally on the effectiveness, cost-effectiveness, and implementation of two multi-strategy interventions in supporting the safe cessation of long-term antidepressants to improve primary health care and outcomes for patients.TRIAL REGISTRATIONANZCTR, ACTRN12622001379707p. Registered on 27 October 2022.
ArticleNumber 615
Audience Academic
Author Freeman, Chris
Scott, Ian
Cleetus, MaryAnne
Zwar, Nicholas
Thrift, Karen
Panahi, Idin
Morgan, Mark
Wallis, Katharine A
Donald, Maria
Horowitz, Mark
Moncrieff, Joanna
Ware, Robert S
Byrnes, Joshua
Author_xml – sequence: 1
  fullname: Wallis, Katharine A
– sequence: 2
  fullname: Donald, Maria
– sequence: 3
  fullname: Horowitz, Mark
– sequence: 4
  fullname: Moncrieff, Joanna
– sequence: 5
  fullname: Ware, Robert S
– sequence: 6
  fullname: Byrnes, Joshua
– sequence: 7
  fullname: Thrift, Karen
– sequence: 8
  fullname: Cleetus, MaryAnne
– sequence: 9
  fullname: Panahi, Idin
– sequence: 10
  fullname: Zwar, Nicholas
– sequence: 11
  fullname: Morgan, Mark
– sequence: 12
  fullname: Freeman, Chris
– sequence: 13
  fullname: Scott, Ian
BookMark eNptks9u1DAQxiNUJNrCC3CyxKUcUvw3cbigVRWg0kpILZwtrz1JXSV2cLKt9r36gMx2K6AIWZZH9vf97BnPSXEUU4SieMvoOWO6-jAzQStRUo6zrmRV3r8ojlktVVlxpo7-il8VJ_N8S6kUjZDHxcNVu25X1y05u2p9hnkOsSfrFPtyafNIVnEJHqb9gY0L2V637z-SKacluTSQLmViiSgtKqds-9EuwRE3bOcFMsk2-jSGGTxxKS45DQOGSw52INB14JZwBxHJZRinAUaIC_pTJDe7TQ6o3E1QMhIi6VGW0YV3oMnB6-JlZ4cZ3jytp8WPz-33i6_l-tuXy4vVunRKsqVk0lXSOy-FV43WugKltefc1VAr5nlDneKKWQm1s6yrNnwjK4uFhA11wm_EaXF54Ppkb82Uw2jzziQbzONGyr2xGR80gFFO0gashkY6hNS2EUpJL3inbSeZQ9anA2vabkbwDrPFlJ5Bn5_EcGP6dGcYVaLmvELC2RMhp59bmBeDxXUwDDZC2s6G65o2DVfNXvruH-lt2uaItUJV1WhKtRZ_VL3FDELsEl7s9lCzqqua0rrRClXn_1Hh8DAG_FjoAu4_M_CDweU0zxm630kyavbdag7darBbzWO3mnvxC3I-4Ts
CitedBy_id crossref_primary_10_1071_PY23168
crossref_primary_10_1071_PY23046
crossref_primary_10_1016_j_jad_2024_04_060
crossref_primary_10_1016_j_jadr_2024_100765
Cites_doi 10.1177/2045125320921694
10.1177/2045125320980573
10.1176/appi.ajp.161.5.826
10.3399/bjgpopen17X101265
10.1016/j.sxmr.2017.07.002
10.2147/PPA.S110632
10.1177/2045125321991274
10.1192/bjp.bp.108.061960
10.1016/j.jpsychires.2023.03.013
10.1097/00005650-199603000-00003
10.1177/0897190012467210
10.1186/1477-7525-10-156
10.3399/BJGP.2020.0913
10.1177/0004867420979353
10.1046/j.1525-1497.2001.016009606.x
10.1177/0004867417721018
10.1016/j.addbeh.2018.08.027
10.1097/NMD.0b013e318156816f
10.1787/ae3016b9-en
10.1177/20451253211039327
10.1177/2045125320967183
10.1370/afm.2094
10.1093/heapro/dal017
10.1177/0269881113517957
10.1097/MLR.0b013e3182408812
10.1177/0004867415621392
10.1007/s40263-022-00960-y
10.1177/2045125320981174
10.1001/archinte.166.10.1092
10.5694/mja2.50522
10.1136/bmj.d4551
10.1016/S0749-3797(01)00350-6
10.1016/S2215-0366(19)30032-X
10.31128/AJGP-02-21-5828
10.1159/000506868
10.1016/j.jad.2018.10.107
10.1192/bjp.bp.108.051110
10.1071/HC17018
10.1080/08870449908407311
10.1192/bja.2021.62
10.7326/0003-4819-146-5-200703060-00004
10.1136/bmjopen-2020-039053
10.1177/20451253231171518
10.1186/1748-5908-4-50
ContentType Journal Article
Copyright COPYRIGHT 2023 BioMed Central Ltd.
The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
BioMed Central Ltd., part of Springer Nature 2023
Copyright_xml – notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: BioMed Central Ltd., part of Springer Nature 2023
DBID AAYXX
CITATION
3V.
7RV
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
KB0
M0S
M1P
NAPCQ
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13063-023-07646-w
DatabaseName CrossRef
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
Medical Database
Nursing & Allied Health Premium
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList


Publicly Available Content Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1745-6215
EndPage 615
ExternalDocumentID oai_doaj_org_article_5c409ea8e94c46a7a93554d32f8af41c
A767007985
10_1186_s13063_023_07646_w
GeographicLocations Australia
Queensland Australia
United Kingdom--UK
GeographicLocations_xml – name: Australia
– name: United Kingdom--UK
– name: Queensland Australia
GrantInformation_xml – fundername: ;
  grantid: MRFAR000079
– fundername: ;
  grantid: PRC3 - 2015744
GroupedDBID ---
-5E
-5G
-A0
-BR
0R~
123
2-G
29Q
2WC
53G
5VS
6PF
7RV
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AEGXH
AENEX
AFKRA
AFPKN
AHBYD
AHYZX
AIAGR
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
C24
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
NAPCQ
O5R
O5S
PGMZT
PIMPY
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
U2A
UKHRP
WOQ
WOW
~8M
3V.
5GY
7XB
8FK
AHMBA
AZQEC
DWQXO
FRP
K9.
PQEST
PQQKQ
PQUKI
PRINS
XSB
7X8
5PM
ID FETCH-LOGICAL-c541t-14c64dcd43d598886e588d22c7e751d290c5251a4e7ca1f6b2b46a306eb0c3db3
IEDL.DBID RPM
ISSN 1745-6215
IngestDate Tue Oct 22 15:10:31 EDT 2024
Tue Sep 17 21:29:20 EDT 2024
Fri Oct 25 09:47:37 EDT 2024
Mon Dec 16 22:53:29 EST 2024
Tue Nov 19 21:44:06 EST 2024
Tue Nov 12 23:47:53 EST 2024
Fri Nov 22 07:15:02 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c541t-14c64dcd43d598886e588d22c7e751d290c5251a4e7ca1f6b2b46a306eb0c3db3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ORCID 0000-0002-2580-9362
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537226/
PQID 2869800883
PQPubID 44365
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_5c409ea8e94c46a7a93554d32f8af41c
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10537226
proquest_miscellaneous_2870992596
proquest_journals_2869800883
gale_infotracmisc_A767007985
gale_infotracacademiconefile_A767007985
crossref_primary_10_1186_s13063_023_07646_w
PublicationCentury 2000
PublicationDate 2023-09-28
PublicationDateYYYYMMDD 2023-09-28
PublicationDate_xml – month: 09
  year: 2023
  text: 2023-09-28
  day: 28
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Current controlled trials in cardiovascular medicine
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – sequence: 0
  name: BioMed Central
– name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References GS Malhi (7646_CR8) 2021; 55
A Bala (7646_CR10) 2018; 6
PC Groot (7646_CR27) 2021; 11
C Coupland (7646_CR13) 2011; 343
MA Horowitz (7646_CR25) 2019; 6
H Maheswaran (7646_CR45) 2012; 10
A Guy (7646_CR22) 2020; 10
7646_CR32
K Kroenke (7646_CR50) 2001; 16
7646_CR31
7646_CR30
R Horne (7646_CR49) 1999; 14
RL Spitzer (7646_CR52) 2006; 166
M Donald (7646_CR39) 2021; 71
K Hodgson (7646_CR43) 2014; 28
K Kroenke (7646_CR53) 2007; 146
E White (7646_CR19) 2021; 11
G Cruickshank (7646_CR21) 2008; 5
J Price (7646_CR11) 2009; 195
F Cosci (7646_CR17) 2020; 89
GM Curran (7646_CR36) 2012; 50
SM Orsillo (7646_CR48) 2007; 195
7646_CR20
SR Kjosavik (7646_CR2) 2016; 50
NR Ogle (7646_CR33) 2013; 26
J Davies (7646_CR16) 2019; 97
7646_CR18
JH Meyer (7646_CR29) 2004; 161
7646_CR14
LJ Damschroder (7646_CR54) 2009; 4
A Framer (7646_CR26) 2021; 11
MJ Huijbers (7646_CR55) 2020; 10
RE Glasgow (7646_CR40) 2001; 21
7646_CR4
R Eveleigh (7646_CR35) 2018; 1
7646_CR1
7646_CR7
C Cartwright (7646_CR12) 2016; 10
R Uher (7646_CR44) 2009; 195
7646_CR6
RE Glasgow (7646_CR41) 2006; 21
J van Os (7646_CR28) 2023; 13
J Brett (7646_CR3) 2017; 51
MP Hengartner (7646_CR15) 2020; 10
7646_CR47
S Gilbody (7646_CR51) 2007; 57
KA Wallis (7646_CR38) 2017; 9
JE Ware (7646_CR42) 1996; 34
MP Hengartner (7646_CR5) 2020; 10
J Read (7646_CR23) 2023; 161
7646_CR46
KA Wallis (7646_CR34) 2021; 50
KA Wallis (7646_CR37) 2017; 15
E Maund (7646_CR24) 2019; 245
J Rothmore (7646_CR9) 2020; 212
References_xml – volume: 10
  start-page: 204512532092169
  year: 2020
  ident: 7646_CR5
  publication-title: Ther Adv Psychopharmacol
  doi: 10.1177/2045125320921694
  contributor:
    fullname: MP Hengartner
– volume: 10
  start-page: 204512532098057
  year: 2020
  ident: 7646_CR15
  publication-title: Ther Adv Psychopharmacol
  doi: 10.1177/2045125320980573
  contributor:
    fullname: MP Hengartner
– volume: 161
  start-page: 826
  issue: 5
  year: 2004
  ident: 7646_CR29
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.161.5.826
  contributor:
    fullname: JH Meyer
– volume: 1
  start-page: 17X101265
  issue: 4
  year: 2018
  ident: 7646_CR35
  publication-title: BJGP Open
  doi: 10.3399/bjgpopen17X101265
  contributor:
    fullname: R Eveleigh
– volume: 6
  start-page: 29
  issue: 1
  year: 2018
  ident: 7646_CR10
  publication-title: Sex Med Rev
  doi: 10.1016/j.sxmr.2017.07.002
  contributor:
    fullname: A Bala
– volume: 10
  start-page: 1401
  year: 2016
  ident: 7646_CR12
  publication-title: Patient Prefer Adherence
  doi: 10.2147/PPA.S110632
  contributor:
    fullname: C Cartwright
– volume: 11
  start-page: 204512532199127
  year: 2021
  ident: 7646_CR26
  publication-title: Ther Adv Psychopharmacol
  doi: 10.1177/2045125321991274
  contributor:
    fullname: A Framer
– volume: 195
  start-page: 202
  issue: 3
  year: 2009
  ident: 7646_CR44
  publication-title: Br J Psychiatry
  doi: 10.1192/bjp.bp.108.061960
  contributor:
    fullname: R Uher
– volume: 161
  start-page: 298
  year: 2023
  ident: 7646_CR23
  publication-title: J Psychiatr Res
  doi: 10.1016/j.jpsychires.2023.03.013
  contributor:
    fullname: J Read
– ident: 7646_CR20
– ident: 7646_CR47
– volume: 5
  start-page: 105
  issue: 2
  year: 2008
  ident: 7646_CR21
  publication-title: Ment Health Fam Med
  contributor:
    fullname: G Cruickshank
– ident: 7646_CR30
– volume: 34
  start-page: 220
  issue: 3
  year: 1996
  ident: 7646_CR42
  publication-title: Med Care
  doi: 10.1097/00005650-199603000-00003
  contributor:
    fullname: JE Ware
– volume: 26
  start-page: 389
  issue: 4
  year: 2013
  ident: 7646_CR33
  publication-title: J Pharm Pract
  doi: 10.1177/0897190012467210
  contributor:
    fullname: NR Ogle
– volume: 10
  start-page: 156
  issue: 1
  year: 2012
  ident: 7646_CR45
  publication-title: Health Qual Life Outcomes
  doi: 10.1186/1477-7525-10-156
  contributor:
    fullname: H Maheswaran
– volume: 71
  start-page: E508
  issue: 708
  year: 2021
  ident: 7646_CR39
  publication-title: Br J Gen Pract
  doi: 10.3399/BJGP.2020.0913
  contributor:
    fullname: M Donald
– volume: 55
  start-page: 7
  issue: 1
  year: 2021
  ident: 7646_CR8
  publication-title: Aust N Z J Psychiatry
  doi: 10.1177/0004867420979353
  contributor:
    fullname: GS Malhi
– volume: 16
  start-page: 606
  issue: 9
  year: 2001
  ident: 7646_CR50
  publication-title: J Gen Intern Med
  doi: 10.1046/j.1525-1497.2001.016009606.x
  contributor:
    fullname: K Kroenke
– ident: 7646_CR6
– volume: 51
  start-page: 990
  issue: 10
  year: 2017
  ident: 7646_CR3
  publication-title: Aust N Z J Psychiatry
  doi: 10.1177/0004867417721018
  contributor:
    fullname: J Brett
– volume: 97
  start-page: 111
  year: 2019
  ident: 7646_CR16
  publication-title: Addict Behav
  doi: 10.1016/j.addbeh.2018.08.027
  contributor:
    fullname: J Davies
– ident: 7646_CR31
– volume: 195
  start-page: 830
  issue: 10
  year: 2007
  ident: 7646_CR48
  publication-title: J Nerv Ment Dis
  doi: 10.1097/NMD.0b013e318156816f
  contributor:
    fullname: SM Orsillo
– ident: 7646_CR1
  doi: 10.1787/ae3016b9-en
– volume: 11
  start-page: 204512532110393
  year: 2021
  ident: 7646_CR27
  publication-title: Ther Adv Psychopharmacol
  doi: 10.1177/20451253211039327
  contributor:
    fullname: PC Groot
– volume: 10
  start-page: 204512532096718
  year: 2020
  ident: 7646_CR22
  publication-title: Ther Adv Psychopharmacol
  doi: 10.1177/2045125320967183
  contributor:
    fullname: A Guy
– volume: 15
  start-page: 341
  issue: 4
  year: 2017
  ident: 7646_CR37
  publication-title: Ann Fam Med
  doi: 10.1370/afm.2094
  contributor:
    fullname: KA Wallis
– ident: 7646_CR7
– volume: 21
  start-page: 245
  issue: 3
  year: 2006
  ident: 7646_CR41
  publication-title: Health Promot Int
  doi: 10.1093/heapro/dal017
  contributor:
    fullname: RE Glasgow
– volume: 28
  start-page: 142
  issue: 2
  year: 2014
  ident: 7646_CR43
  publication-title: J Psychopharmacol
  doi: 10.1177/0269881113517957
  contributor:
    fullname: K Hodgson
– volume: 50
  start-page: 217
  issue: 3
  year: 2012
  ident: 7646_CR36
  publication-title: Med Care
  doi: 10.1097/MLR.0b013e3182408812
  contributor:
    fullname: GM Curran
– volume: 50
  start-page: 1180
  issue: 12
  year: 2016
  ident: 7646_CR2
  publication-title: Aust N Z J Psychiatry
  doi: 10.1177/0004867415621392
  contributor:
    fullname: SR Kjosavik
– ident: 7646_CR14
  doi: 10.1007/s40263-022-00960-y
– volume: 11
  start-page: 204512532098117
  year: 2021
  ident: 7646_CR19
  publication-title: Ther Adv Psychopharmacol
  doi: 10.1177/2045125320981174
  contributor:
    fullname: E White
– volume: 57
  start-page: 650
  issue: 541
  year: 2007
  ident: 7646_CR51
  publication-title: Br J Gen Pract
  contributor:
    fullname: S Gilbody
– volume: 166
  start-page: 1092
  issue: 10
  year: 2006
  ident: 7646_CR52
  publication-title: Arch Intern Med
  doi: 10.1001/archinte.166.10.1092
  contributor:
    fullname: RL Spitzer
– volume: 212
  start-page: 329
  issue: 7
  year: 2020
  ident: 7646_CR9
  publication-title: Med J Aust
  doi: 10.5694/mja2.50522
  contributor:
    fullname: J Rothmore
– volume: 343
  start-page: d4551
  year: 2011
  ident: 7646_CR13
  publication-title: BMJ
  doi: 10.1136/bmj.d4551
  contributor:
    fullname: C Coupland
– volume: 21
  start-page: 189
  issue: 3
  year: 2001
  ident: 7646_CR40
  publication-title: Am J Prev Med
  doi: 10.1016/S0749-3797(01)00350-6
  contributor:
    fullname: RE Glasgow
– ident: 7646_CR32
– volume: 6
  start-page: 538
  issue: 6
  year: 2019
  ident: 7646_CR25
  publication-title: Lancet Psychiatry
  doi: 10.1016/S2215-0366(19)30032-X
  contributor:
    fullname: MA Horowitz
– volume: 50
  start-page: 954
  issue: 12
  year: 2021
  ident: 7646_CR34
  publication-title: Aust J Gen Pract
  doi: 10.31128/AJGP-02-21-5828
  contributor:
    fullname: KA Wallis
– volume: 89
  start-page: 283
  issue: 5
  year: 2020
  ident: 7646_CR17
  publication-title: Psychother Psychosom
  doi: 10.1159/000506868
  contributor:
    fullname: F Cosci
– volume: 245
  start-page: 38
  year: 2019
  ident: 7646_CR24
  publication-title: J Affect Disord
  doi: 10.1016/j.jad.2018.10.107
  contributor:
    fullname: E Maund
– volume: 195
  start-page: 211
  issue: 3
  year: 2009
  ident: 7646_CR11
  publication-title: Br J Psychiatry
  doi: 10.1192/bjp.bp.108.051110
  contributor:
    fullname: J Price
– volume: 9
  start-page: 145
  issue: 2
  year: 2017
  ident: 7646_CR38
  publication-title: J Prim Health Care
  doi: 10.1071/HC17018
  contributor:
    fullname: KA Wallis
– volume: 14
  start-page: 1
  issue: 1
  year: 1999
  ident: 7646_CR49
  publication-title: Psychol Health
  doi: 10.1080/08870449908407311
  contributor:
    fullname: R Horne
– ident: 7646_CR18
  doi: 10.1192/bja.2021.62
– ident: 7646_CR4
– ident: 7646_CR46
– volume: 146
  start-page: 317
  issue: 5
  year: 2007
  ident: 7646_CR53
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-146-5-200703060-00004
  contributor:
    fullname: K Kroenke
– volume: 10
  start-page: e039053
  issue: 11
  year: 2020
  ident: 7646_CR55
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2020-039053
  contributor:
    fullname: MJ Huijbers
– volume: 13
  start-page: 204512532311715
  year: 2023
  ident: 7646_CR28
  publication-title: Ther Adv Psychopharmacol
  doi: 10.1177/20451253231171518
  contributor:
    fullname: J van Os
– volume: 4
  start-page: 50
  issue: 1
  year: 2009
  ident: 7646_CR54
  publication-title: Implement Sci
  doi: 10.1186/1748-5908-4-50
  contributor:
    fullname: LJ Damschroder
SSID ssj0043934
ssj0017864
Score 2.413151
Snippet Background Many people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or...
Many people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or ongoing need...
BackgroundMany people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or...
BACKGROUNDMany people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or...
Abstract Background Many people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
StartPage 615
SubjectTerms Analysis
Antidepressants
Automation
Clinical practice guidelines
Consent
Deprescribing
Discontinuation
Dosage and administration
Drug dosages
Drug withdrawal
Elder care
Falls (Accidents)
Family medicine
Health care reform
Intervention
Medical care, Cost of
Medical practice software
Medical research
Mental health
Patient outcomes
Patients
Physicians (General practice)
Primary care
Psychotherapy
Psychotropic drugs
R&D
Research & development
Services
Sexual disorders
Study Protocol
Tapering
Well being
Withdrawal
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fa9UwFA6yB_FF_InVKREEFQm7-dnEt6t0DNl82BzsLaRJendha8ddL8P_yz_Qk7Qdqz744kOhNCm0-U5OvtOe8wWhd4YHTb2sCasFBCiOaeKAlhOgDiYueOMXPtU7H31XB6fi25k8u7PVV8oJG-SBh4Hbkx4ikOh0NMIL5UqXBMFF4KzRrhHUZ--7YFMwNfhgWGW5mEpktNq7Bk-d_1fCUSqhyM1sGcpq_X_75D_zJO8sPPuP0MORMeLl8KSP0b3YPkH3j8Z_4k_Rr-PqsFqeVPjDcRVyVmu7wodduyJ9tbnEy7Zfj-muMIh4e1J9_IyTOkMHJoCBsmKHOXHQ82rjVlnAFfuLbdJPwLCOhQ4MIQY8prRfwGne6AMPiSCjryTryykPPQGNz3-mQjCcvu8SitctXg3q1ngqynqGTverH18PyLgXA_FS0J5Q4ZUIPggepIGoWUWpdWDMl7GUNDCz8BKokhOx9I42qgbslYNRj_XC81Dz52in7dr4AmEjHW9MQ0vHklwZcLxAZV3yWkdO4VqBPk3Q2KtBcsPmUEUrOwBpAUibgbQ3BfqS0LvtmeSy8wUwIjsakf2XERXofcLepkkNSHs31ibAAyd5LLssUzVTabQs0O6sJ2Dg582T9djRGVxbppUBXq41L9Db2-Z0Z0pwa2O3TX1K4OoQi6oC6ZnVzd5s3tKuz7MgOE2iPMCjX_6PsXiFHrA8UQxhehft9JttfA3Eq6_f5Dn2G8B_LbU
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1di9QwFA26gvgifmLXVSIIKhJ20qRJ6ouM0mWRXR92XZi3kCZpd2C3HeeDxf_lD_Qmk45WwYeBockwbc_NzbnJvScIvS6ZU9QWNclrDgGKyRUxQMsJUIfST1hjJzbUO59-FccX_MusmKUFt1VKqxx8YnTUrrdhjfwwV6IEcqMU-7j4TsKpUWF3NR2hcRvdoTlM5WDPcrYLuKhUgg-FMkocrsBfx11L-EjBBbkZTUZRs_9fz_x3tuQf08_RA3Q_8UY83QL9EN3y3SN09zTtjD9GP8-qk2p6XuG3Z5WLua1di0_6riXranmNp916npJe4VXizXn17gMOGg09GAIG4ooNZsRAz8XStFHGFdurTVBRwDCbuR7MwTucEtuv4Gs87gNv00GSxyTz6yEbPcCNL3-EcjAcVnkJxfMOt1uNazyUZj1BF0fVt8_HJJ3IQGzB6ZpQbgV31nHmihJiZ-ELpVyeW-llQV1eTmwBhMlwL62hjajBAoSBt-7riWWuZk_RXtd3_hnCZWFYUzZUmjyIlgHTc7SoJauVZxSuZej9AI1ebIU3dAxYlNBbIDUAqSOQ-iZDnwJ6u55BNDte6JetTmNQFxaCWW-UL7mF25ImaMtzx_JGmYZTm6E3AXsdhjYgbU2qUIAbDiJZeipDTZMsVZGhg1FPwMCOmwfr0cklrPRvA87Qq11z-GVIc-t8vwl9JDB2iEhFhtTI6kZPNm7p5pdRFpwGaR5g0_v___fn6F4eh0BJcnWA9tbLjX8BxGpdv4yj5xfmxSUi
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1dixMxFA3rCuKL-Imjq0QQVCTafE5GEKkyyyJbH3Yt7FvIJJluoTuzdlvW_V_-QG_SmeLoPvlQKJMEpjn3Juc2954g9LLgXlMnK8IqAQGKZZpYoOUEqEMRRrx2IxfrnSff1MFUfD2RJzuov-6om8CLa0O7eJ_UdLl49_PH1Sdw-I_J4bV6fwHrcDqNhE-uhCKXN9BNBjtjTPGaiO2pAuy9XPSFM9eOG2xOScP_35X67-zJP7aj_bvoTscj8XgD_D20E5r76NakOyl_gH4dlYfl-LjEr49Kn3Jdmxk-bJsZWZXLMzxuVvMuCRamFq-PyzcfcNRsaMEwMBBZbDEnFnqeL-0sybpit1hHVQUMu5tvwTyCx12i-wK-pus_8CY9pFtByfysz06P8OPTq1gehuO_voTieYNnG81r3JdqPUTT_fL7lwPS3dBAnBR0RahwSnjnBfeygFhaBam1Z8zlIZfUs2LkJBAoK0LuLK1VBRahLMx6qEaO-4o_QrtN24THCBfS8rqoaW5ZFDED5ueprHJe6cApPMvQ2x4ac74R4jApgNHKbIA0AKRJQJrLDH2O6G17RhHt9KBdzkznk0Y6CG6D1aEQDl4rt1FrXnjOam1rQV2GXkXsTTQ-QNrZrmIBXjiKZplxHmuc8kLLDO0NegIGbtjcW4_pLdwwrQpg61rzDL3YNseRMe2tCe069smBwUOEqjKkB1Y3-GXDlmZ-mmTCaZTqAXb95P-HPkW3WXKPgjC9h3ZXy3V4BiRsVT1PnvUb4vE0TQ
  priority: 102
  providerName: Scholars Portal
Title RELEASE (REdressing Long-tErm Antidepressant uSE): protocol for a 3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1 in general practice
URI https://www.proquest.com/docview/2869800883
https://search.proquest.com/docview/2870992596
https://pubmed.ncbi.nlm.nih.gov/PMC10537226
https://doaj.org/article/5c409ea8e94c46a7a93554d32f8af41c
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1da9swFBVtB2MvY5_MXRc0GGxjqIktWZb35haXEppSkhXyJmRJTgOJHdKEsv-1H7gr2S7z9raHOMaSQfbR1T3XvvcYoU8pNSLUcUGigkGAoiJBFNByAtQhtSNa6pF29c6Ta355y8bzeH6AeFcL45P2dbE8rVbr02p553MrN2s97PLEhjeT89CJkABvGB6iQ_C_XYzerL_gYSnrymMEH97DKu3fVcIv4YyTh54L8kr9_67Hf-dI_uF0Ll6g5y1bxFkzqpfowFav0NNJ-z78Nfo1za_ybJbjL9Pc-IzWaoGv6mpBdvl2jbNqt2xTXeEG4v0s__odO2WGGuDHQFexwpQo6LnZqoUXb8V6tXfaCRh8mKlhEliD23T2Fez6j3zgJgmkXSfJct3loDuQ8d1PVwSG3bNdEuJlhReNsjXuCrLeoNuL_Mf5JWm_w0B0zMIdCZnmzGjDqIlTiJi5jYUwUaQTm8ShidKRjoEmKWYTrcKSF4A7V3DXbTHS1BT0LTqq6sq-QziNFS3TMkxU5KTKgN-ZMC4SWghLQzgWoG8dNHLTyG1IH6YILhsgJQApPZDyIUBnDr3Hnk4q2x-otwvZThgZawhhrRI2ZRqGlSinKM8MjUqhShbqAH122Etn0IC0Vm1dAgzYSWPJLHGVTEkq4gCd9HoCBrrf3M0e2S4E9zISPAVOLgQN0MfHZnemS26rbL13fRLg6RCH8gCJ3qzrXVm_BWzDi4F3tnD8_6e-R88ibx4picQJOtpt9_YDUK1dMQD7micD9CTLxrMx_J_l1zfTgX9wAdsJEwNve78Bv4QyiQ
link.rule.ids 230,314,727,780,784,864,885,2102,12056,21388,24318,27924,27925,31719,31720,33744,33745,43310,43805,53791,53793,73745,74302
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1db9MwFLWgk4CXiU8RNsBISICQtSaxHYcX1KFMBdoKdZu0N8uxna7SlpR-aOJ_8QO5dp1CQOKhUhW7apJzfX2ufe8xQq_z1IhYs5IkJYUARSWCKKDlBKhDbvtppfva1TuPJ3x4Tr9csIuw4LYKaZWtT_SO2jTarZEfJYLnQG6ESD8uvhN3apTbXQ1HaNxGe045nfXQ3nEx-Tbd7SNkgtO2VEbwoxV4bL9vCZ-MU05uOtORV-3_1zf_nS_5xwR0ch_tB-aIB1uoH6Bbtn6I7ozD3vgj9HNajIrBaYHfTgvjs1vrGR419Yysi-U1HtTreUh7hZeJN6fFuw_YqTQ0YAoYqCtWOCUKei6WauaFXLG-2jgdBQzzmWnAIKzBIbX9Cr76Az_wNiEk-Ewyv27z0R3g-PKHKwjDbp2XxHhe49lW5Rq3xVmP0flJcfZpSMKZDEQzGq9JTDWnRhuaGpZD9MwtE8Ikic5sxmKT5H3NgDIpajOt4oqXYANcwVu3ZV-npkyfoF7d1PYpwjlTaZVXcaYSJ1sGXM_ErMzSUtg0hmsRet9CIxdb6Q3pQxbB5RZICUBKD6S8idCxQ2_X08lm-wvNcibDKJRMQzhrlbA51XBbmXLq8tSkSSVURWMdoTcOe-kGNyCtVahRgBt2MllykLmqpiwXLEKHnZ6Age42t9Yjg1NYyd8mHKFXu2b3S5foVttm4_pkwNkhJuUREh2r6zxZt6WeX3ph8NiJ8wCffvb_f3-J7g7PxiM5-jz5eoDuJX445CQRh6i3Xm7sc6BZ6_JFGEu_AMPiKXg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwGLWgkyZeEFeRMcBISICQ1Sa-xOEFdZBqQFdNHZP2Zjm201XaktKLJv4XP5DPqVMISDxUimJHTfJdfByf7xihVxm1Mja8IEnBYIKiE0k0wHIC0CFzA1qagfH1zicTcXzOvlzwi8B_WgVaZZsTm0Rta-O_kfcTKTIAN1LSfhloEaefRh8W34nfQcqvtIbtNG6jPRgVB0kP7R3lk9Ppbk0hlYK1ZTNS9FeQvZs1TPilggly0xmaGgX_f_P039zJPwaj0T10N6BIPNya_T665aoHaP8krJM_RD-n-TgfnuX4zTS3DdO1muFxXc3IOl9e42G1ngcKLLxYvDnL377HXrGhBrfAAGOxxpRo6LlY6lkj6orN1cZrKmAY22wNzuEsDjT3KzhsNv_AW3JIyJ9kft1y073x8eUPXxyG_TdfEuN5hWdbxWvcFmo9Quej_NvHYxL2ZyCGs3hNYmYEs8YyankGM2nhuJQ2SUzqUh7bJBsYDvBJM5caHZeiAH8QGt66KwaG2oI-Rr2qrtwThDOuaZmVcaoTL2EGuM_GvEhpIR2N4VyE3rWmUYutDIdqpi9SqK0hFRhSNYZUNxE68tbb9fQS2s2JejlTISIVNzC1dVq6jBm4rVR7pXlmaVJKXbLYROi1t73ygQ6WNjrUK8ANe8ksNUx9hVOaSR6hw05PsIHpNrfeo0KCWKnf7hyhl7tmf6UnvVWu3vg-KeB3mJ-KCMmO13WerNtSzS8bkfDYC_UAtj74_7-_QPsQRmr8efL1KbqTNNGQkUQeot56uXHPAHGti-chlH4BiuQtpQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=RELEASE+%28REdressing+Long-tErm+Antidepressant+uSE%29%3A+protocol+for+a+3-arm+pragmatic+cluster+randomised+controlled+trial+effectiveness-implementation+hybrid+type-1+in+general+practice&rft.jtitle=Trials&rft.au=Wallis%2C+Katharine+A.&rft.au=Donald%2C+Maria&rft.au=Horowitz%2C+Mark&rft.au=Moncrieff%2C+Joanna&rft.date=2023-09-28&rft.pub=BioMed+Central&rft.eissn=1745-6215&rft.volume=24&rft_id=info:doi/10.1186%2Fs13063-023-07646-w&rft.externalDBID=PMC10537226
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon